Trials / Active Not Recruiting
Active Not RecruitingNCT05029960
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
Detailed description
In this study, subjects will receive usual treatment for their brain tumor. In addition, they will be given brivaracetam at a dose of 50 mg twice daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brivaracetam | Dose of 50 mg twice daily for 6 months |
Timeline
- Start date
- 2022-05-17
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
- First posted
- 2021-09-01
- Last updated
- 2024-08-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05029960. Inclusion in this directory is not an endorsement.